February 13, 2020
Otsuka Pharmaceutical said on February 12 that its US subsidiary Astex Pharmaceuticals’ novel cancer agent ASTX727 has been accepted for priority review by the US FDA for the treatment of myelodysplastic syndrome (MDS) including chronic myelomonocytic leukemia (CMML). The FDA...read more